Drugs / nL-ATN1-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07221760 | Nov 2025 → Nov 2027 expected | dentatorubral-pallidoluysian atrophy | n-Lorem Foundation | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-ATN1-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07221760 ↗ |
| Modality | Antisense oligonucleotide | “personalized antisense oligonucleotide (ASO) drug” NCT07221760 ↗ |